VIP Polyclonal antibody
VIP Polyclonal Antibody for IF, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
IHC, IF
Conjugate
Unconjugated
Cat no : 16233-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IHC detected in | human colon tissue, human small intestine tissue, mouse brain tissue, rat small intestine tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF detected in | COLO 320 cells, mouse colon tissue |
Recommended dilution
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
Immunofluorescence (IF) | IF : 1:50-1:500 |
Sample-dependent, check data in validation data gallery |
Published Applications
IF | See 2 publications below |
Product Information
16233-1-AP targets VIP in IHC, IF applications and shows reactivity with human, mouse, rat samples.
Tested Reactivity | human, mouse, rat |
Cited Reactivity | mouse |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | VIP fusion protein Ag8933 |
Full Name | vasoactive intestinal peptide |
Calculated molecular weight | 169 aa, 19 kDa |
GenBank accession number | BC009794 |
Gene symbol | VIP |
Gene ID (NCBI) | 7432 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
IHC protocol for VIP antibody 16233-1-AP | Download protocol |
IF protocol for VIP antibody 16233-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Pharm Biol Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4 + type 9 helper T cells and the VIP-VPAC2 signalling pathway | ||